Deciphera Pharmaceuticals, Inc. (DCPH) 是一家上市公司 属于 医疗保健 板块，经营于 制药 - 专科与仿制药 行业. 公司总部位于 Waltham, MA, 美国. 现任CEO为 Steven L. Hoerter.
DCPH 拥有 IPO日期为 2017-09-28, 355 名全职员工, 在 NASDAQ Global Select, 市值为 $2.21B.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
